Page header

Recommendation of the President – Efluelda (trivalent influenza vaccine (split virion), inactivated)

On 22 April 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 53/2026 on the inclusion of the medicinal product Efluelda (trivalent influenza vaccine (split virion), inactivated) in the reimbursement program for the following indication: active immunization of adults aged 60 and older for the prevention of influenza

Publication in Public Information Bulletin (BIP) >>